KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment: 2023-2025

Historic Asset Writedowns and Impairment for Supernus Pharmaceuticals (SUPN) over the last 2 years, with Sep 2025 value amounting to -$239,000.

  • Supernus Pharmaceuticals' Asset Writedowns and Impairment fell 724.14% to -$239,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 63.34%. This contributed to the annual value of $8.9 million for FY2024, which is 55.92% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Asset Writedowns and Impairment of -$239,000 as of Q3 2025, which was down 125.98% from $920,000 recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Asset Writedowns and Impairment peaked at $20.2 million during Q4 2023, and registered a low of -$239,000 during Q3 2025.
  • Its 3-year average for Asset Writedowns and Impairment is $3.8 million, with a median of $825,000 in 2024.
  • Data for Supernus Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY tumbled of 724.14% (in 2025) over the last 5 years.
  • Over the past 3 years, Supernus Pharmaceuticals' Asset Writedowns and Impairment (Quarterly) stood at $20.2 million in 2023, then tumbled by 65.81% to $6.9 million in 2024, then crashed by 724.14% to -$239,000 in 2025.
  • Its Asset Writedowns and Impairment was -$239,000 in Q3 2025, compared to $920,000 in Q2 2025 and $547,000 in Q1 2025.